Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.
The present study investigated the effects of the selective neurokinin-2 (NK2) receptor antagonist SR48968 in behavioral, electrophysiological, and biochemical tests sensitive to the action of prototypical antidepressants (fluoxetine, imipramine) or to corticotropin-releasing factor (CRF) receptor antagonists, which have been proposed recently as potential antidepressants. Results showed that SR48968 (0.3-10 mg/kg i.p.) produced antidepressant-like activity because it reduced immobility in the forced swimming test in both mice and rats, and decreased the amount of maternal separation-induced vocalizations in guinea pig pups. This latter effect appears to involve a reduction of stress-induced substance P release because SR48968 reduced the separation-induced increase in the number of neurons displaying neurokinin-1 receptor internalization in the amygdala. Furthermore, SR48968 increased the expression of the cAMP response-element binding protein mRNA in the rat hippocampus after repeated (1 mg/kg i.p., 21 days), but not acute administration. Finally, neuronal firing of the locus coeruleus (LC) and noradrenergic (NE) release in the prefrontal cortex both elicited by an uncontrollable stressor or an intraventricular administration of CRF were reduced by SR48968 (0.3-1 mg/kg i.p.). The finding that SR48968 (1 mg/kg i.p.) blocked the cortical release of NE induced by an intra-LC infusion of the preferential NK2 receptor agonist neurokinin A suggested the presence of NK2 receptors in this latter region. Importantly, SR48965 (1-10 mg/kg i.p.), the optical antipode of SR48968, which is devoid of affinity for the NK2 receptor, was inactive in all the models used. These data suggest that NK2 receptor blockade may constitute a novel mechanism in the treatment of depression and CRF-related disorders.
Steinberg
R
R
Central Nervous System Research Department, Sanofi-Synthélabo Recherche, Montpellier, France. regis.steinber@sanofi-synthelabo.com
Alonso
R
R
Griebel
G
G
Bert
L
L
Jung
M
M
Oury-Donat
F
F
Poncelet
M
M
Gueudet
C
C
Desvignes
C
C
Le Fur
G
G
Soubrié
P
P
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D001923:Brain Chemistry / Q000502:physiology; D003346:Corticotropin-Releasing Hormone / Q000097:blood*; D017362:Cyclic AMP Response Element-Binding Protein / Q000096:biosynthesis; D006168:Guinea Pigs; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D017403:In Situ Hybridization; D008125:Locus Coeruleus / Q000502:physiology; D008426:Maternal Deprivation; D051379:Mice; D017551:Microdialysis; D009638:Norepinephrine / Q000097:blood; D010880:Piperidines / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000502:physiology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors*; D013550:Swimming / Q000523:psychology; D014828:Vocalization, Animal / Q000187:drug effects
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D017362:Cyclic AMP Response Element-Binding Protein; D010880:Piperidines; D012333:RNA, Messenger; D018041:Receptors, Neurokinin-2; C073839:SR 48968; D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine